University of Heidelberg
Faculty of Medicine Mannheim
University Hospital Mannheim
News
These pages are still under constructions and will be available soon! Please check again later!
Note


If you have questions concerning a specific publication please use this form with subject 'information about publications' and giving the full citation in the message body.

Links
Home > Publications > Abstract >

Monitoring of irradiated brain metastases using MR perfusion imaging and 1H MR spectroscopy

M. Weber, M. Lichy, C. Thilmann, M. Günther, P. Bachert, A. Maudsley, S. Delorme, L. Schad, J. Debus and H. Schlemmer

Radiologe, 43 (5), pp.388-395

PURPOSE. In follow-up examinations of irradiated brain metastases conventional contrast-enhanced morphological MR imaging is often unable to distinguish between transient radiation effects, radionecrosis,and tumor recurrence. To evaluate changes of relative cerebral blood flow (rCBF) in irradiated brain metastases arterial spin-labeling techniques (ASL) were applied and compared to the outcome of (1)H MR spectroscopy and spectroscopic imaging ((1)H MRS, SI). PATIENTS AND METHODS. In 2 patients follow-up examinations of irradiated brain metastases were performed on a 1.5-T tomograph (average single dose: 20 Gy/80\% isodose). Relative CBF values of gray matter (GM), white matter (WM),and metastases (Met) were measured by means of the ASL techniques ITS-FAIR and Q2TIPS. (1)H MRS was performed with PRESS 1500/135. RESULTS. In both patients with initially hyperperfused metastases (Met/GM >1) the reduction of rCBF after stereotactic radiosurgery indicated response to treatment-even if the contrast-enhancing region increased-while increasing rCBF values indicated tumor progression. The findings were confirmed by (1)H MRS, SI and subsequent follow-up. CONCLUSION. The ASL techniques ITS-FAIR and Q2TIPS are able to monitor changes of rCBF in irradiated brain metastases. The two cases imply a possible role for ASL-MR perfusion imaging and (1)H MR spectroscopy in differentiating radiation effects from tumor progression.

Contact: Dr. Frank Zöllner last modified: 20.03.2019
to top of page